Hyperthermia payment boost
This article was originally published in The Gray Sheet
CMS proposes to raise reimbursement for procedure codes applicable to BSD Medical's cancer treatment systems by 86% in the 2008 hospital outpatient payment 1proposal released July 16, according to the firm. CMS will finalize the rates in November, to be effective Jan. 1. BSD markets hyperthermia systems, which kill cancer cells with focused heat and may improve the effectiveness of radiation and chemotherapy by increasing blood flow. The firm filed a response July 30 to questions FDA had on its March PMA submission for the BSD-2000 deep hyperthermia system, providing new data from a Dutch study with 12-year follow-up of patients treated with advanced cervical cancer (2"The Gray Sheet" Jan. 9, 2006, p. 15)...
You may also be interested in...
BSD Medical plans to submit a PMA application by the end of the quarter for its non-invasive BSD-2000 tumor hyperthermia therapy system to treat cancer
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.